DK2739311T3 - Fremgangsmåde til behandling af knoglespaltedefekter - Google Patents
Fremgangsmåde til behandling af knoglespaltedefekter Download PDFInfo
- Publication number
- DK2739311T3 DK2739311T3 DK12746235.6T DK12746235T DK2739311T3 DK 2739311 T3 DK2739311 T3 DK 2739311T3 DK 12746235 T DK12746235 T DK 12746235T DK 2739311 T3 DK2739311 T3 DK 2739311T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- bone
- antibody
- sclerostin
- sclerostin antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Effektiv mængde af et anti-sclerostin antistof til anvendelse i en fremgangsmåde til behandling af en knoglespaltedefekt hos et pattedyrsindivid, hvor antistoffet er en sclerostin-hæmmer, hvilken fremgangsmåde omfatter administration af antistoffet til individet, hvor anti-sclerostin-antistoffet administreres over en behandlingsperiode, der mindst varer 20 uger, og hvor knoglespaltedefekten omfatter en spalte mellem to knoglesegmenter på mindst 5 mm.
2. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge krav 1, hvor anti-sclerostin-antistoffet administreres i en ugentlig dosis fra 1 mg/kg til 50 mg/kg pr. uge.
3. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge krav 1, hvor behandlingsperioden varer 28 uger.
4. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge krav 1, hvor knoglespaltedefekten er udvalgt fra gruppen bestående af en komminut fraktur, en ikke-sammenvokset fraktur, en segmentarisk skeletdefekt, kirurgisk frembragte knogledefekter, kirurgisk behandlede knogledefekter og knogledefekter fremkommet ved traumatisk læsion af knoglen eller sygdom (herunder arthritis, udviklingsdeformitet, tumorfjernelse (resektion) eller fjernelse af infektion).
5. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge krav 4, hvor knoglespaltedefekten er frembragt ved fjernelse af inficerede knoglesektioner eller fjernelse af cancer fra knoglen.
6. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge krav 1, hvor fremgangsmåden endvidere omfatter administration af et andet knoglestyrkende terapeutisk middel udvalgt fra gruppen bestående af parathyroideahormon, et bisphosphonat, et RANKL-antistof og et DKK-1-antistof.
7. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge et hvilket som helst af kravene 1-6, hvor anti-sclerostin-antistoffet administreres: (a) i en mængde af 30 mg/kg pr. uge; og/eller (b) én gang ugentligt i behandlingsperiodens varighed.
8. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge et hvilket som helst af kravene 1-7, hvor behandling med anti-sclerostin-antistoffet ikke resulterer i en væsentlig stigning i kortikal porøsitet i individets knogle.
9. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge et hvilket som helst af kravene 1-8, hvor anti-sclerostin-antistoffet administreres subkutant.
10. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge et hvilket som helst af kravene 1-9, hvor anti-sclerostin-antistoffet er et immunoglobulin, der omfatter en tungkæde og en ledkæde.
11. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge et hvilket som helst af kravene 1-9, hvor anti-sclerostin-antistoffet er et antistof eller fragment deraf, der udviser en bindingsaffinitet for sclerostin ifølge SEQ ID NO: 1 på mindre end eller lig med 1 x 10'7 M.
12. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge et hvilket som helst af kravene 1-11, hvor anti-sclerostin-antistoffet binder til et sclerostin-polypeptid, der omfatter aminosyresekvensen ifølge SEQ ID NO: 1, hvor: (a) anti-sclerostin-antistoffet binder til sekvensen af SEQ ID NO: 6; (b) anti-sclerostin-antistoffet binder til sekvensen af mindst én af SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 eller SEQ ID NO: 5; eller (c) anti-sclerostin-antistoffet binder til sekvensen af mindst én af SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72 eller SEQ ID NO: 73.
13. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge et hvilket som helst af kravene 1-11, hvor anti-sclerostin-antistoffet tværblokerer bindingen af mindst ét af antistofferne Ab-A, Ab-B, Ab-C, Ab-D, Ab-1, Ab-2, Ab-3, Ab-4, Ab-5, Ab-6, Ab-7, Ab-8, Ab-9, Ab-10, Ab-11, Ab-12, Ab-13, Ab-14, Ab-15, Ab-16, Ab-17, Ab-18, Ab-19, Ab-20, Ab-21, Ab-22, Ab-23 og Ab-24 til sclerostin og/eller er tværblokeret mod binding til sclerostin af mindst ét af antistofferne Ab-A, Ab-B, Ab-C, Ab-D, Ab-1, Ab-2, Ab-3, Ab-4, Ab-5, Ab-6, Ab-7, Ab-8, Ab-9, Ab-10, Ab-11, Ab-12, Ab- 13, Ab-14, Ab-15, Ab-16, Ab-17, Ab-18, Ab-19, Ab-20, Ab-21, Ab-22, Ab-23 og Ab-24, hvor antistofferne Ab-A til Ab-D og Ab-1 til Ab-24 har de tung- og letkædesekvenser, der er identificeret i figur 1.
14. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge et hvilket som helst af kravene 1-11, hvor anti-sclerostin-antistoffet omfatter en CDR-H1 ifølge SEQ ID NO: 245, en CDR-H2 ifølge SEQ ID NO: 246, en CDR-H3 ifølge SEQ ID NO: 247, en CDR-L1 ifølge SEQ ID NO: 78, en CDR-L2 ifølge SEQ ID NO: 79 og en CDR-L3 ifølge SEQ ID NO: 80.
15. Anti-sclerostin-antistof til anvendelse i fremgangsmåden ifølge krav 14, hvor anti-sclerostin-antistof: (a) omfatter tungkæder, der omfatter SEQ ID NO: 378 og letkæder, der omfatter SEQ ID NO 376; eller (b) har tungkæder ifølge SEQ ID NO: 145 eller SEQ ID NO: 392 og letkæder ifølge SEQ ID NO: 141.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515191P | 2011-08-04 | 2011-08-04 | |
| PCT/US2012/049331 WO2013019954A1 (en) | 2011-08-04 | 2012-08-02 | Method for treating bone gap defects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2739311T3 true DK2739311T3 (da) | 2018-04-23 |
Family
ID=46650942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12746235.6T DK2739311T3 (da) | 2011-08-04 | 2012-08-02 | Fremgangsmåde til behandling af knoglespaltedefekter |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10538584B2 (da) |
| EP (1) | EP2739311B9 (da) |
| JP (4) | JP6301832B2 (da) |
| AU (1) | AU2012290083B2 (da) |
| CA (1) | CA2842432C (da) |
| CY (1) | CY1120666T1 (da) |
| DK (1) | DK2739311T3 (da) |
| ES (1) | ES2667554T3 (da) |
| HR (1) | HRP20180736T1 (da) |
| HU (1) | HUE039786T2 (da) |
| LT (1) | LT2739311T (da) |
| MX (1) | MX355816B (da) |
| NO (1) | NO2739311T3 (da) |
| PL (1) | PL2739311T3 (da) |
| PT (1) | PT2739311T (da) |
| SI (1) | SI2739311T1 (da) |
| WO (1) | WO2013019954A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| CA2815181C (en) * | 2010-10-27 | 2020-09-15 | William Gleason Richards | Dkk1 antibodies and methods of use |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2015087187A1 (en) * | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
| US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| KR102876829B1 (ko) | 2018-06-13 | 2025-10-27 | 스트리커 유로피안 오퍼레이션즈 리미티드 | 골편을 수집 및 처리하기 위한 장치 및 수술 시스템 |
| EP4424337B1 (en) | 2019-12-18 | 2025-10-01 | Stryker European Operations Limited | Bone fragment collector and processor |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1391707A (en) | 1918-08-15 | 1921-09-27 | Viviano Philip | Automatic change-speed transmission |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法 |
| US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
| WO1992006693A1 (en) | 1990-10-22 | 1992-04-30 | Fox Chase Cancer Center | Dna construct for providing rna therapy |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| WO1994028929A1 (en) | 1993-06-07 | 1994-12-22 | Genentech, Inc. | Hiv envelope polypeptides |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| EP0756628B1 (en) | 1994-04-29 | 2007-11-14 | Curis, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
| DE4427221A1 (de) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
| US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| WO1997044461A2 (en) | 1996-05-22 | 1997-11-27 | Novopharm Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| US6117911A (en) | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| JP2001512016A (ja) | 1997-08-01 | 2001-08-21 | ジェンセット | 筋肉およびその他中胚葉組織中で発現される分泌タンパク質の５’ｅｓｔ |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| DE69934227T2 (de) | 1998-06-19 | 2007-10-04 | Mcgill University, Montreal | Auf Beta-Arabinose und dessen Analoga basierte Antisense-Oligonukleotide |
| US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| ATE481487T1 (de) | 1998-11-27 | 2010-10-15 | Ucb Sa | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
| JP2002536968A (ja) | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Ｋｄｒに特異的な抗体およびその使用 |
| EP1657256B1 (en) | 1999-06-09 | 2009-10-07 | Genentech, Inc. | Compositions and methods for the treatment of tumor |
| JP2003525611A (ja) | 2000-03-02 | 2003-09-02 | アムジェン インコーポレーテッド | コルディン様−２分子およびその使用 |
| JP2003534813A (ja) | 2000-06-01 | 2003-11-25 | アムジェン インコーポレーテッド | シスチンノットポリペプチド：ｃｌｏａｋｅｄ−２分子およびその使用 |
| EP1366156A2 (en) | 2000-06-19 | 2003-12-03 | F. Hoffmann-La Roche Ag | Osteolevin gene polymorphisms |
| JP4451059B2 (ja) | 2000-09-01 | 2010-04-14 | ジェネンテック インコーポレイテッド | 分泌及び膜貫通ポリペプチドとそれをコードする核酸 |
| AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| DE10145772A1 (de) | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
| BRPI0214680B1 (pt) | 2001-12-06 | 2018-09-18 | Biocontrol Systems, Inc. | instrumento para uso em monitorar um produto, um ingrediente, um ambiente ou processo, instrumento para detectar emissão de luz de uma amostra e método de monitorar uma amostra de um produto, um ingrediente, um processo ou ambiente |
| US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
| AU2003223214B2 (en) | 2002-03-01 | 2008-09-18 | Celltech R & D, Inc. | Methods to increase or decrease bone density |
| US7799523B2 (en) | 2002-04-03 | 2010-09-21 | Celltech R & D, Inc. | Association of polymorphisms in the SOST gene region with bone mineral density |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| US20040023356A1 (en) | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
| WO2004098491A2 (en) | 2002-11-01 | 2004-11-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES |
| US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
| MXPA05009805A (es) | 2003-03-14 | 2006-04-18 | Celltech R & D Inc | Ligandos para proteinas de enlace tgf-beta y usos de los mismos. |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| GB0324854D0 (en) | 2003-10-24 | 2003-11-26 | Expresson Biosystems Ltd | App/ena antisense |
| US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
| WO2006015373A2 (en) | 2004-08-04 | 2006-02-09 | Amgen Inc | Antibodies to dkk-1 |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| EP1981910B1 (en) | 2006-01-13 | 2013-06-26 | A Chan Holding B.V. | Method for identifying inhibitor of the glypican-sclerostin interaction |
| EP2423226A3 (en) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
| EP3345607B1 (en) | 2006-12-29 | 2022-10-26 | Ossifi-Mab LLC | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| EP2114435A1 (en) | 2007-02-02 | 2009-11-11 | Novartis AG | Modulators of sclerostin binding partners for treating bone-related disorders |
| MY149129A (en) * | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| BRPI0820327A2 (pt) | 2007-11-02 | 2020-10-06 | Novartis Ag | moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6) |
| CN101896201A (zh) | 2007-12-14 | 2010-11-24 | 安进公司 | 使用抗硬骨素抗体治疗骨折的方法 |
| CA2726087A1 (en) | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
| AR075715A1 (es) | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| CA2815181C (en) | 2010-10-27 | 2020-09-15 | William Gleason Richards | Dkk1 antibodies and methods of use |
-
2012
- 2012-08-02 SI SI201231257T patent/SI2739311T1/en unknown
- 2012-08-02 US US14/233,137 patent/US10538584B2/en active Active
- 2012-08-02 AU AU2012290083A patent/AU2012290083B2/en active Active
- 2012-08-02 ES ES12746235.6T patent/ES2667554T3/es active Active
- 2012-08-02 HU HUE12746235A patent/HUE039786T2/hu unknown
- 2012-08-02 HR HRP20180736TT patent/HRP20180736T1/hr unknown
- 2012-08-02 MX MX2014001416A patent/MX355816B/es active IP Right Grant
- 2012-08-02 NO NO12746235A patent/NO2739311T3/no unknown
- 2012-08-02 WO PCT/US2012/049331 patent/WO2013019954A1/en not_active Ceased
- 2012-08-02 JP JP2014524076A patent/JP6301832B2/ja active Active
- 2012-08-02 LT LTEP12746235.6T patent/LT2739311T/lt unknown
- 2012-08-02 EP EP12746235.6A patent/EP2739311B9/en active Active
- 2012-08-02 PL PL12746235T patent/PL2739311T3/pl unknown
- 2012-08-02 CA CA2842432A patent/CA2842432C/en active Active
- 2012-08-02 DK DK12746235.6T patent/DK2739311T3/da active
- 2012-08-02 PT PT127462356T patent/PT2739311T/pt unknown
-
2017
- 2017-05-31 JP JP2017107279A patent/JP2017214374A/ja active Pending
-
2018
- 2018-05-03 CY CY181100463T patent/CY1120666T1/el unknown
-
2019
- 2019-05-08 JP JP2019087955A patent/JP2019167348A/ja active Pending
- 2019-12-26 US US16/726,989 patent/US20200115444A1/en not_active Abandoned
-
2021
- 2021-07-26 JP JP2021121157A patent/JP2021183610A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SI2739311T1 (en) | 2018-07-31 |
| MX355816B (es) | 2018-05-02 |
| LT2739311T (lt) | 2018-06-11 |
| WO2013019954A1 (en) | 2013-02-07 |
| NO2739311T3 (da) | 2018-07-21 |
| JP2019167348A (ja) | 2019-10-03 |
| CA2842432A1 (en) | 2013-02-07 |
| CY1120666T1 (el) | 2019-12-11 |
| AU2012290083A1 (en) | 2014-03-13 |
| CA2842432C (en) | 2022-10-04 |
| HRP20180736T1 (hr) | 2018-06-29 |
| HUE039786T2 (hu) | 2019-02-28 |
| EP2739311B1 (en) | 2018-02-21 |
| JP6301832B2 (ja) | 2018-03-28 |
| AU2012290083B2 (en) | 2017-07-20 |
| US10538584B2 (en) | 2020-01-21 |
| ES2667554T3 (es) | 2018-05-11 |
| ES2667554T9 (es) | 2018-10-01 |
| EP2739311B9 (en) | 2018-09-19 |
| JP2014521692A (ja) | 2014-08-28 |
| PT2739311T (pt) | 2018-03-26 |
| PL2739311T3 (pl) | 2018-08-31 |
| EP2739311A1 (en) | 2014-06-11 |
| MX2014001416A (es) | 2014-10-17 |
| US20200115444A1 (en) | 2020-04-16 |
| JP2017214374A (ja) | 2017-12-07 |
| US20140271654A1 (en) | 2014-09-18 |
| JP2021183610A (ja) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200115444A1 (en) | Methods for treating bone gap defects | |
| US20240269274A1 (en) | Treatment for bone diseases | |
| US9913900B2 (en) | Method of treating alvelor bone loss through the use of anti-sclerostin antibodies | |
| EP2699261B1 (en) | Method for treating osteoporosis | |
| HK1196251A (en) | Method for treating bone gap defects | |
| HK1196251B (en) | Method for treating bone gap defects | |
| HK40037737A (en) | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies | |
| HK1198367B (en) | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |